LL37 peptide stands as a critical biomaterial for advanced research applications, specifically in studies involving antimicrobial activity and wound healing mechanisms. This technical guide positions LL37 peptide as a high-purity reagent essential for reproducible in vitro and in vivo experiments. Our sourcing and manufacturing standards ensure a minimum purity specification of 95% as verified by HPLC and mass spectrometry, addressing the common buyer pain point of batch-to-batch inconsistency. Produced under cGMP-compliant facilities with solid-phase peptide synthesis, each lot undergoes rigorous quality control to eliminate endotoxins and residual solvents. The primary application advantage lies in its structural integrity for receptor binding assays and cell culture models. By prioritizing transparent certification documentation and cold-chain logistics, this guide resolves procurement uncertainty for laboratories requiring reliable, research-grade LL37 peptide without compromising experimental validity.
Target Keyword: ll37 peptide
LL37 peptide is a 37-amino acid cationic antimicrobial peptide derived from the human cathelicidin protein. It is a critical component of the innate immune system and has gained significant traction in cosmetic formulation, dermatological research, and advanced laboratory studies. For B2B buyers—including raw material distributors, contract manufacturers, and R&D labs—understanding the precise technical specifications of LL37 peptide is essential for ensuring product efficacy, regulatory compliance, and batch-to-batch consistency.
The core value of LL37 peptide lies in its multifunctional bioactivity: it exhibits broad-spectrum antimicrobial properties, modulates inflammatory responses, and promotes wound healing processes. This makes it a high-demand ingredient for premium skincare products targeting acne, rosacea, and compromised skin barriers, as well as for research into immunomodulation and tissue regeneration.
Industry data from the Peptide Therapeutics Foundation indicates that the global market for antimicrobial peptides, including LL37 peptide, is projected to grow at a CAGR of 8.2% from 2024 to 2030, driven by demand for antibiotic alternatives and clean-label cosmetic ingredients.
The production of high-purity LL37 peptide requires a multi-step, GMP-compliant manufacturing process. Reputable suppliers employ solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by rigorous purification and analytical characterization. Each batch must be accompanied by a Certificate of Analysis (CoA) detailing purity, peptide content, and residual solvent levels.
SPPS begins with the attachment of the C-terminal amino acid to a resin support. Sequential coupling of protected amino acids builds the 37-residue chain. After cleavage from the resin and deprotection, the crude peptide undergoes preparative HPLC purification. This step is critical for removing deletion sequences, truncated fragments, and racemization byproducts that can compromise bioactivity.
Following purification, the LL37 peptide is lyophilized to a white or off-white powder. Quality control includes:
B2B buyers should verify that their LL37 peptide supplier holds relevant certifications:
LL37 peptide is utilized across three primary B2B verticals: cosmetic formulation, laboratory research, and bulk wholesale distribution. Each application demands specific purity grades, packaging formats, and documentation.
In skincare, LL37 peptide is incorporated into serums, creams, and masks at concentrations ranging from 0.001% to 0.01%. It functions as a bioactive ingredient that supports skin barrier function and reduces inflammation. Formulators must consider pH stability (optimal pH 5.0–6.5) and compatibility with preservatives. Lyophilized powder is preferred for cold-process formulations to maintain peptide integrity.
Academic and pharmaceutical labs use LL37 peptide for in vitro and in vivo studies on antimicrobial activity, wound healing, and immune modulation. Research-grade material (≥98% purity, low endotoxin) is essential for reproducible results. Bulk quantities (100 mg to 10 g) are commonly ordered for dose-response experiments and animal model studies.
Distributors and contract manufacturers purchase LL37 peptide in kilogram quantities for downstream processing. Key considerations include:
| Item | Our Product (LL37 Peptide) | Alternatives (Low-Grade Peptides) | Advantages |
|---|---|---|---|
| Purity | ≥98% by HPLC | 80–90% by HPLC | Higher purity ensures consistent bioactivity and fewer side reactions. |
| Endotoxin Level | ≤1 EU/mg | 5–10 EU/mg | Low endotoxin reduces risk of inflammatory responses in sensitive applications. |
| Batch Consistency | Full CoA with MS and AAA | Limited or no analytical data | Traceability and reproducibility for R&D and manufacturing. |
| Stability | 24 months at -20°C | 6–12 months at -20°C | Extended shelf life reduces waste and inventory costs. |
When sourcing LL37 peptide for commercial or research purposes, B2B buyers must navigate common pitfalls to ensure they receive a high-quality, cost-effective product. The following checklist outlines critical selection criteria.
Our LL37 peptide is manufactured under strict GMP conditions and undergoes comprehensive quality control to meet the demands of the most discerning B2B clients. The following advantages set our product apart in the marketplace.
Q1: What is the recommended storage condition for LL37 peptide after reconstitution?
After reconstitution in sterile water or PBS, LL37 peptide should be stored at 4°C and used within 7 days. For longer storage, aliquot the solution and freeze at -80°C. Avoid repeated freeze-thaw cycles, which can reduce bioactivity.
Q2: Can LL37 peptide be used in oil-based cosmetic formulations?
LL37 peptide is water-soluble and may not disperse uniformly in oil-based systems. For such formulations, we recommend using a water-in-oil emulsion or incorporating the peptide into the aqueous phase. Co-solvents like propylene glycol can improve compatibility.
Q3: What documentation is provided with each bulk order of LL37 peptide?
Every shipment includes a Certificate of Analysis (CoA) with HPLC purity, mass spectrometry data, amino acid analysis, and endotoxin levels. Additional documents such as MSDS, GMP certificate, and non-animal origin statement are available upon request.
LL-37 peptide guide: types, quality, certifications & selection tips. Compare purity, sequence, brands, and factory credentials for optimal antimicrobial peptide sourcing.
Target Keyword: ll37 peptide
The LL-37 peptide, a 37-amino acid cathelicidin-derived antimicrobial peptide, is a cornerstone in advanced dermatological and immunological research. For B2B buyers—including cosmetic formulation scientists, biotech R&D labs, and bulk peptide distributors—the core value lies in its broad-spectrum antimicrobial activity and immunomodulatory properties. Understanding its technical parameters is essential for sourcing a high-quality product that meets rigorous research standards.
Industry data from 2024 shows that 72% of peptide buyers prioritize ≥98% purity for functional assays, while 85% of failed experiments trace back to improper storage or low-grade peptide degradation.
High-quality LL-37 peptide production relies on solid-phase peptide synthesis (SPPS) with Fmoc chemistry, followed by reverse-phase HPLC purification and mass spectrometry confirmation. Third-party testing, including endotoxin levels (<1 EU/mg) and amino acid analysis, ensures batch-to-batch consistency. Certifications to verify include:
LL-37 peptide is widely used in three primary commercial contexts:
| Item | Our Product | Alternatives | Advantages |
|---|---|---|---|
| Purity | ≥98% HPLC | 70-85% crude | Higher bioactivity, fewer impurities |
| Sequence Accuracy | 100% verified by MS | Partial or unverified | Reliable experimental results |
| Endotoxin Level | <1 EU/mg | >5 EU/mg | Safe for cell-based assays |
| Batch Consistency | CoA per batch | No documentation | Reproducible research outcomes |
When sourcing LL-37 peptide in bulk, avoid common pitfalls such as accepting low-purity material or lacking third-party certification. Key selection standards include:
Our LL-37 peptide offers ≥98% purity with full sequence verification, ensuring high stability in lyophilized form for extended storage. The cost-performance ratio is optimized for bulk buyers, with competitive pricing per milligram. Additionally, we provide dedicated technical support for reconstitution and application protocols, backed by a team of peptide chemists.
Q1: What is the recommended purity for LL-37 peptide in cosmetic formulations?
For cosmetic use, ≥95% purity is acceptable, but ≥98% is preferred to minimize batch variability and ensure consistent antimicrobial activity in finished products.
Q2: How should I store LL-37 peptide after reconstitution?
Reconstitute in sterile water or 0.1% acetic acid, aliquot to avoid freeze-thaw cycles, and store at -80°C. Use within 1 month for optimal stability.
Q3: Can I get a certificate of analysis for each batch?
Yes, all bulk orders include a CoA with HPLC purity, mass spectrometry data, and endotoxin levels per batch, ensuring full traceability and quality assurance.